Company Description
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally.
The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old.
It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Aytu BioPharma, Inc. is headquartered in Denver, Colorado.
| Country | United States |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Joshua Disbrow |
Contact Details
Address: Denver Corporate Center III, Suite 920 Denver, Colorado 80237 United States | |
| Phone | (720) 437-6580 |
| Website | aytubio.com |
Stock Details
| Ticker Symbol | AYTU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001385818 |
| CUSIP Number | 054754874 |
| ISIN Number | US0547548588 |
| Employer ID | 47-0883144 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua R. Disbrow | Chief Executive Officer and Director |
| Jarrett T. Disbrow Ph.D. | Chief Business Officer |
| Greg Pyszczymuka | Chief Commercial Officer |
| Ryan J. Selhorn CPA | Chief Financial Officer, Corporate Secretary and Treasurer |
| Margaret Cabano | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | ARS | Filing |
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 12, 2025 | 10-Q | Quarterly Report |
| Feb 12, 2025 | 8-K | Current Report |
| Dec 4, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |